Health Care [ 6/12 ] | Health Care Technology [ 27/73 ]
NASDAQ | Common Stock
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
The company operates through Integra and Scienture segments.
The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products.
The Scienture segment researches and develops branded pharmaceutical products.
The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia.
Scienture Holdings, Inc. is based in Tampa, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 18, 25 | -0.48 Increased by +63.56% | - |
| Apr 21, 25 | -0.33 Decreased by -101.59% | - |
| Mar 25, 25 | -0.82 Increased by +93.68% | - |
| Nov 29, 24 | -1.34 Increased by +70.66% | - |
| Jul 22, 24 | -1.30 Increased by +55.02% | - |
| Apr 24, 24 | 20.49 Increased by +2.13 K% | - |
| Mar 25, 24 | -12.95 Decreased by -769.07% | - |
| Oct 25, 23 | -4.57 Decreased by -399.78% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by -100.00% | -6.72 M Decreased by -266.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 10.26 K Decreased by -99.56% | -3.06 M Decreased by -114.42% | Decreased by -29.87 K% Decreased by -3.41 K% |
| Dec 31, 24 | 53.08 K Decreased by -86.47% | -7.16 M Decreased by -103.19% | Decreased by -13.49 K% Decreased by -1.40 K% |
| Sep 30, 24 | 64.86 K Decreased by -83.47% | -3.18 M Increased by +9.69% | Decreased by -4.91 K% Decreased by -446.22% |
| Jun 30, 24 | 18.70 K Decreased by -94.90% | -1.83 M Increased by +7.14% | Decreased by -9.81 K% Decreased by -1.72 K% |
| Mar 31, 24 | 2.35 M Increased by +376.86% | 21.25 M Increased by +3.23 K% | Increased by +903.15% Increased by +757.18% |
| Dec 31, 23 | 392.29 K Decreased by -84.49% | -3.53 M Decreased by -281.02% | Decreased by -898.61% Decreased by -2.36 K% |
| Sep 30, 23 | 392.29 K Decreased by -80.92% | -3.53 M Decreased by -600.81% | Decreased by -898.61% Decreased by -3.57 K% |